secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2022-09-15T23:59:59+00:00
Accession:  0001104659-22-100245
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Phase 2 ELX-02 CF trial misses efficacy endpoints; lung exposure low
--------------------------------------------------------------------------

- Combination of ELX-02 with ivacaftor did not achieve statistical significance for changes in SCC or FEV1.
- ELX-02 was well tolerated; no treatment-related serious adverse events reported.
- Evidence of activity seen in patients with higher baseline sweat chloride (p=0.00013 at Day 35).
- Steady-state lung drug levels averaged 2 µM, only 20% of lowest preclinical active concentration.
- Company plans to start proof-of-concept trial for ELX-02 in Alport syndrome later in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922100245/0001104659-22-100245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922100245/tm2225930d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-100245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer